|
|
 Previous Article | Table of Contents | Next Article 
Chronic Thrombocytopenia Is Induced in Dogs by Development of Cross-Reacting Antibodies to the MpL Ligand
David C. Dale,
Janet L. Nichol,
Douglas A. Rich,
Dawn M. Best,
Sherrill J. Slichter,
William Sheridan, and
Pam Hunt
From the Department of Medicine, University of Washington and the Puget Sound Blood Center, Seattle, WA; and Amgen, Thousand Oaks, CA.
The MpL ligand (ML) is a potent stimulus for thrombocytopoiesis. To create an in vivo model of ML deficiency, we injected dogs with a recombinant human ML (rhML) to determine whether cross-reacting antibodies would develop and cause thrombocytopenia. RhML was administered subcutaneously for 8 weeks to three normal dogs (mean platelets, 197 ± 5.5 × 103/µL). Within 5 days their platelet counts were twice baseline and greater than 4 times baseline by day 21. Then, uniformly, chronic thrombocytopenia developed. At 1 week after terminating rhML, mean platelets were 0.5 times baseline and at 2 months 0.25 times baseline. Early in treatment, marrow biopsies showed increased megakaryocyte number and ploidy, which decreased as platelets declined. Paralleling these changes, high titer anti-rhML antibodies developed. Autologous 51Cr-labeled platelet recovery and survival measurements indicated that the thrombocytopenia was principally due to decreased production. Infusion of plasma from the thrombocytopenic dogs into two normal dogs and one dog previously made thrombocytopenic with rhML caused platelet counts to fall gradually. These studies show that dogs with anti-rhML antibodies develop thrombocytopenia, presumably because the cross-reacting antibodies neutralize endogenous canine ML. The results strongly suggest that ML plays an essential role in maintaining normal platelet levels.
Blood, Vol. 90 No. 9 (November 1), 1997:
pp. 3456-3461
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
I. C. Haznedaroglu, H. Goker, M. Turgut, Y. Buyukasik, and M. Benekli
Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2002;
8(3):
193 - 212.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W Fureder, U Firbas, J L Nichol, J Pistillo, S Winkler, H Hiesberger, W R Sperr, J Smolen, and G Schett
Serum thrombopoietin levels and anti-thrombopoietin antibodies in systemic lupus erythematosus
Lupus,
April 1, 2002;
11(4):
221 - 226.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. L. Basser, E. O'Flaherty, M. Green, M. Edmonds, J. Nichol, D. M. Menchaca, B. Cohen, and C. G. Begley
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor
Blood,
April 1, 2002;
99(7):
2599 - 2602.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Li, C. Yang, Y. Xia, A. Bertino, J. Glaspy, M. Roberts, and D. J. Kuter
Thrombocytopenia caused by the development of antibodies to thrombopoietin
Blood,
December 1, 2001;
98(12):
3241 - 3248.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Schiffer, K. Miller, R. A. Larson, P. C. Amrein, J. H. Antin, V. J. Zani, and R. M. Stone
A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia
Blood,
April 15, 2000;
95(8):
2530 - 2535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Goerner, B. Bruno, P. A. McSweeney, G. Buron, R. Storb, and H.-P. Kiem
The Use of Granulocyte Colony-Stimulating Factor During Retroviral Transduction on Fibronectin Fragment CH-296 Enhances Gene Transfer Into Hematopoietic Repopulating Cells in Dogs
Blood,
October 1, 1999;
94(7):
2287 - 2292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-A. Abina, M. Tulliez, M.-T. Duffour, N. Debili, C. Lacout, J.-L. Villeval, F. Wendling, W. Vainchenker, and H. Haddada
Thrombopoietin (TPO) Knockout Phenotype Induced by Cross-Reactive Antibodies Against TPO Following Injection of Mice with Recombinant Adenovirus Encoding Human TPO
J. Immunol.,
May 1, 1998;
160(9):
4481 - 4489.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
